Bayer promoting Actron's small pill size as benefit over Orudis KT, other analgesics.
This article was originally published in The Tan Sheet
Executive Summary
BAYER EMPHASIZING ACTRON's SMALL PILL SIZE as a benefit over its competitors in press materials announcing the product's Jan. 9 launch into the analgesics market. Among the competing products facing Actron are Whitehall-Robins' Rx-to-OTC switch ketoprofen, Orudis KT, which has been on the market since November, Procter-Syntex' Aleve and other established analgesics.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning